These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2600869)

  • 1. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury.
    Mathias CJ; Luckitt J; Desai P; Baker H; el Masri W; Frankel HL
    J Rehabil Res Dev; 1989; 26(4):9-16. PubMed ID: 2600869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.
    Nance PW; Bugaresti J; Shellenberger K; Sheremata W; Martinez-Arizala A
    Neurology; 1994 Nov; 44(11 Suppl 9):S44-51; discussion S51-2. PubMed ID: 7970010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of tizanidine.
    Roberts RC; Part NJ; Pokorny R; Muir C; Leslie GC; Emre M
    Neurology; 1994 Nov; 44(11 Suppl 9):S29-31. PubMed ID: 7970008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments.
    Gracies JM; Nance P; Elovic E; McGuire J; Simpson DM
    Muscle Nerve Suppl; 1997; 6():S92-120. PubMed ID: 9826984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.
    Granfors MT; Backman JT; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2004 Dec; 76(6):598-606. PubMed ID: 15592331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction.
    Granfors MT; Backman JT; Neuvonen M; Ahonen J; Neuvonen PJ
    Clin Pharmacol Ther; 2004 Apr; 75(4):331-41. PubMed ID: 15060511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics.
    Momo K; Homma M; Osaka Y; Inomata S; Tanaka M; Kohda Y
    J Clin Pharmacol; 2010 Mar; 50(3):331-7. PubMed ID: 19789372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.
    Wagstaff AJ; Bryson HM
    Drugs; 1997 Mar; 53(3):435-52. PubMed ID: 9074844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spasticity: current and future management. Royal College of Physicians, November 13, 1997.
    Hosp Med; 1998 Jan; 59(1):61-9. PubMed ID: 9798568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An approach to switching patients from baclofen to tizanidine.
    Brenner R; Hyman N; Knobler R; O'Brien M; Stephan T
    Hosp Med; 1998 Oct; 59(10):778-82. PubMed ID: 9850294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of oral alpha 2 adrenergic agonists, clonidine and tizanidine, on tetracaine spinal anesthesia].
    Omote K; Satoh O; Sonoda H; Kumeta Y; Yamaya K; Namiki A
    Masui; 1995 Jun; 44(6):816-23. PubMed ID: 7637157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2.
    Granfors MT; Backman JT; Laitila J; Neuvonen PJ
    Clin Pharmacol Ther; 2005 Oct; 78(4):400-11. PubMed ID: 16198659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers.
    Shah J; Wesnes KA; Kovelesky RA; Henney HR
    Clin Ther; 2006 Sep; 28(9):1308-17. PubMed ID: 17062304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonidine-induced bradycardia in patients with spinal cord injury.
    Rosenblum D
    Arch Phys Med Rehabil; 1993 Nov; 74(11):1206-7. PubMed ID: 8239963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
    Groves L; Shellenberger MK; Davis CS
    Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
    Smolenski C; Muff S; Smolenski-Kautz S
    Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective assessment of tizanidine for spasticity due to acquired brain injury.
    Meythaler JM; Guin-Renfroe S; Johnson A; Brunner RM
    Arch Phys Med Rehabil; 2001 Sep; 82(9):1155-63. PubMed ID: 11552184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state.
    Shellenberger MK; Groves L; Shah J; Novack GD
    Drug Metab Dispos; 1999 Feb; 27(2):201-4. PubMed ID: 9929503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative profile of tizanidine in the management of spasticity.
    Lataste X; Emre M; Davis C; Groves L
    Neurology; 1994 Nov; 44(11 Suppl 9):S53-9. PubMed ID: 7970011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud).
    Emre M; Leslie GC; Muir C; Part NJ; Pokorny R; Roberts RC
    J Neurol Neurosurg Psychiatry; 1994 Nov; 57(11):1355-9. PubMed ID: 7964811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.